A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It plans to enroll 100 participants.

Also called NCT01785771

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01785771
Other papers using this trial's data
  • Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA1c: The FREEDOM-1 HBL (High Baseline) Study Diabetes care, 2018-03 DOI, PubMed 29301824

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01785771. Allocation not applicable; no masking; primary purpose treatment. Start 2013-05 (registry gives no type); primary completion 2018-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c
Intervention (Drug)
ITCA 650 (exenatide in DUROS)
Lead sponsor
Intarcia Therapeutics (class: industry)

Record details

Record id
cardio:ct-nct01785771
Content hash
867af78e2d0b4fcd28439867f96f5d5b54ab3a3a5b3b97ab22efc3681e741670